Oncosec Medical (ONCS) Provides 2018 Business Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
OncoSec Provides 2018 Business Outlook
January 3, 2018 8:01 AM ESTSAN DIEGO, Jan. 3, 2018 /PRNewswire/ --Â OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, announced its anticipated operational milestones for 2018 and a review of business highlights for year-end 2017.
"The momentum we achieved in late 2017 provides the foundation for a transformational year in 2018," said Daniel J. O'Connor, Chief Executive Officer of OncoSec. "The year ahead is critical for OncoSec with preliminary data expected in key clinical programs;  preliminary feedback from regulators on an accelerated approval pathway for ImmunoPulse® IL-12 in unresectable metastatic melanoma... More



